2 results
Approved WMORecruiting
The current study has been designed to demonstrate that MOCA using Flebogrif is not inferior to EVLA for the treatment of GSV insufficiency.
Approved WMOPending
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and pertuzumab as maintenance therapy in subjects with advanced HER2+ breast cancer who have had prior treatment with a taxane, trastuzumab, and pertuzumab.